Nunzia Pharmaceutical Company
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NUNZ research report →
Companywww.nunziapharma.com
Nunzia Pharmaceutical Company operates as a pharmaceutical and nutraceutical company. The company owns the right to manufacture, market, and distribute Nunzia, a nutraceutical that treats autism, fragile X, ADHD, PTSD, and other disorders. It offers its products through wholesalers, as well as through its website nunziapharma.
- CEO
- Sara Gonzales
- IPO
- 2009
- Employees
- 4
- HQ
- Long Beach, CA, US
Price Chart
Valuation
- Market Cap
- $43.45K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.32
- EV/EBITDA
- -0.00
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 101661.22%
- ROIC
- -2387913.98%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-78,064,632 · 22.72%
- EPS
- $-0.26 · 25.71%
- Op Income
- $-78,060,908
- FCF YoY
- 99.04%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -2.60
- Avg Volume
- 4.86K
Get TickerSpark's AI analysis on NUNZ
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 30, 06 | HENRY G DAVID | buy | 25,000 |
| Oct 18, 06 | HENRY G DAVID | buy | 100,000 |
| Jun 14, 06 | HENRY G DAVID | buy | 10,000 |
| May 3, 06 | HENRY G DAVID | buy | 3,913 |
| May 2, 06 | HENRY G DAVID | buy | 55,000 |
| Apr 28, 06 | HENRY G DAVID | buy | 110,000 |
| Apr 14, 06 | Hitz Kingman L | other | 500,000 |
| Jan 30, 06 | HENRY G DAVID | sell | 5,386,667 |
| Dec 16, 05 | HENRY G DAVID | other | 2,500,000 |
| Dec 16, 05 | HENRY G DAVID | other | 1,250,000 |
Our NUNZ Coverage
We haven't published any research on NUNZ yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NUNZ Report →